Claims for Patent: 11,839,597

Summary for Patent: 11,839,597

Title:	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Abstract:	Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Inventor(s):	Claire Megret, Herve Guillard, Jean-Francois Dubuisson
Assignee:	Flamel Ireland Ltd
Application Number:	US17/194,780
Patent Claims:	1. A formulation for the once-nightly treatment of narcolepsy Type 1 or Type 2 in a human patient in need thereof, the formulation comprising a single bedtime daily dose of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate, wherein the formulation provides an effective six to eight hours of sleep to a human patient in need thereof. 2. The formulation of claim 1, wherein the formulation produces a Cmax that is less than the Cmax of a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 3. The formulation of claim 1, wherein the formulation decreases the number of cataplexy attacks (NCA), compared to a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 4. The formulation of claim 1, wherein the formulation decreases the polysomnogram (PSG) transitions from N/2 to N/3 and rapid eye movement (REM) sleep to wake and N1 sleep, compared to a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 5. The formulation of claim 1, wherein the formulation decreases the number of arousals or wakenings obtained from a polysomnogram, compared to a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 6. The formulation of claim 1, wherein the formulation decreases the disturbed nocturnal sleep (DNS), the disturbed nocturnal events, or the adverse respiratory events as determined by polysomnographic measures of sleep fragmentation, compared to a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 7. The formulation of claim 1, wherein the formulation decreases the daytime sleepiness when measured by the Maintenance of Wakefulness Test based on EEG measures of wakefulness, compared to a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 8. The formulation of claim 1, wherein the formulation decreases the hypnagogic hallucinations or sleep paralysis symptoms in Type 1 narcolepsy patients, compared to a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 9. The formulation of claim 1, wherein the formulation increases the mean sleep latency compared to a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 10. The formulation of claim 1, wherein the formulation decreases the excessive daytime sleepiness (EDS) as measured by patient report via the Epworth Sleepiness Scale (ESS), compared to a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 11. The formulation of claim 1, wherein the formulation the improves the Clinical Global Impression (CGI) rating of sleepiness, compared to a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 12. The formulation of claim 1, wherein the formulation improves the Maintenance of Wakefulness Test, Clinical Global Impression rating, and cataplexy attack frequency, compared to a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 13. A formulation for the once-nightly treatment of narcolepsy Type 1 or Type 2 in a human patient in need thereof, the formulation comprising a single bedtime daily dose of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate, wherein the formulation is effective to induce sleep for at least six consecutive hours for a human patient in need thereof, wherein the formulation produces less confusion, less depressive syndrome, less incontinence, less nausea, or less sleepwalking, compared to a dosing regimen consisting of administering half the dose at t0 and another half of the dose at t4h of an immediate release liquid solution of sodium oxybate. 14. The formulation of claim 13, wherein the formulation produces a Cmax that is less than the Cmax of the dosing regimen of the immediate release liquid solution of sodium oxybate. 15. The formulation of claim 13, wherein the formulation decreases the number of cataplexy attacks (NCA), compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 16. The formulation of claim 13, wherein the formulation decreases the PSG transitions from N/2 to N/3 and REM sleep to wake and N1 sleep, compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 17. The formulation of claim 13, wherein the formulation decreases the number of arousals or wakenings obtained from a polysomnogram, compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 18. The formulation of claim 13, wherein the formulation decreases disturbed nocturnal sleep (DNS), disturbed nocturnal events, or adverse respiratory events as determined by polysomnographic measures of sleep fragmentation, compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 19. The formulation of claim 13, wherein the formulation decreases daytime sleepiness when measured by the Maintenance of Wakefulness test based on EEG measures of wakefulness, compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 20. The formulation of claim 13, wherein the formulation decreases hypnagogic hallucinations or sleep paralysis symptoms in Type 1 narcolepsy patients, compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 21. The formulation of claim 13, wherein the formulation increases mean sleep latency compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 22. The formulation of claim 13, wherein the formulation decreases excessive daytime sleepiness (EDS) as measured by patient report via the Epworth Sleepiness Scale (ESS), compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 23. The formulation of claim 13, wherein the formulation produces less confusion compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 24. The formulation of claim 13, wherein the formulation produces less depressive syndrome compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 25. The formulation of claim 13, wherein the formulation produces less incontinence, compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 26. The formulation of claim 13, wherein the formulation produces less sleep walking, compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 27. The formulation of claim 13, wherein the formulation produces less nausea, compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 28. The formulation of claim 13, wherein the formulation improves the Clinical Global Impression (CGI) rating of sleepiness, compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 29. The formulation of claim 13, wherein the formulation improves the Maintenance of Wakefulness Test, Clinical Global Impression rating, and cataplexy attack frequency, compared to the dosing regimen of the immediate release liquid solution of sodium oxybate. 30. A formulation for the once-nightly treatment of narcolepsy Type 1 or Type 2 in a human patient in need thereof, the formulation comprising a single bedtime daily dose of gamma-hydroxybutyrate equivalent to from 3.0 to 12.0 g of sodium oxybate, wherein the formulation provides at least six consecutive hours of sleep to a human patient in need thereof.